

Catalog Number: CM03564

## 产品信息

**Catalog Number:**  
CM03564

**CAS号:**  
188817-13-2


**分子式:**  
 $C_{17}H_{12}ClF_3N_2O$

**主要靶点:**  
COX

**主要通路:**  
神经科学|免疫与炎症

**分子量:**  
352.74

**溶解度:**  
DMSO:35.3 mg/mL (100 mM)



## 靶点活性

COX-1:9 nM.

## 体外活性

将COX-1与SC-560预先孵育可浓度依赖性地抑制花生四烯酸向PGE<sub>2</sub>的转化。SC-560对COX-2的IC<sub>50</sub>为6.3 μM，约为对COX-1的1000倍。SC-560展示了剂量和时间依赖性地抑制HCC细胞生长的效应。同时，SC-560在剂量依赖的方式下抑制软琼脂中的集落形成，并诱导HCC细胞发生凋亡。此外，SC-560降低了抗凋亡蛋白survivin和XIAP的水平，并在剂量和时间依赖的方式中激活caspase 3和7。

## 体内活性

在检测前1小时口服10或30 mg/kg SC-560可完全抑制离子刺激物刺激的TxB<sub>2</sub>生成，这表明SC-560具有口服生物利用度，可在体内抑制COX-1。SC-560广泛分布于大鼠组织中，CL值接近肝血浆流量。口服后，该化合物的生物利用度低于15%，并显示出肾毒性。

## 动物实验

**Rat:** The pharmacokinetics of SC-560 is studied in Sprague-Dawley rats after a single intravenous (i.v.) and oral dose (10 mg/kg) in polyethylene glycol (PEG) 600 and a single oral dose (10 mg/kg) in 1% methylcellulose (MC). Serial blood samples are collected via a catheter inserted in the right jugular vein and serum samples are analysed for SC-560 using reverse phase HPLC. After oral administration of SC-560 in PEG, urine is also collected for 24 h and analyzed for urinary sodium, chloride, and potassium as well as NAG.

## 细胞实验

SC-560 is dissolved in DMSO[2].HuH-6 and HA22T/VGH cells (5000/well) are treated with various concentrations of SC-560 (5, 10, 25, 50, 100, 200 μM) and cultured for 72 h. At the end of treatment, cell viability is assessed by MTS assay.

## 储存

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.